Of the patients with IDH2 mutations, two without CH (2.5%) and one patient (3.2%) with CH underwent maintenance therapy with enasidenib after ASCT, while one patient with CH and FLT3-ITD received midostaurin maintenance, and 8 patients with adverse risk cytogenetics and good response to induction treatment underwent autologous transplantation in the absence of an available donor or because the patients declined allogeneic transplantation. This evidence concerns the gene IDH2 and cyclic hematopoiesis.